Therapeutic indications: Civasta is indicated as monotherapy for the short-term treatment of primary insomnia characterised by poor quality of sleep in patients who are aged 55 or over.
Click here for complete product code information.
ADVERSE EVENTS SHOULD BE REPORTED
Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/.
Adverse events should also be reported to Neuraxpharm UK Ltd by:
- Email: pv-uk@neuraxpharm.com
- Phone number: +44 330 128 0919